Additional file 1 of A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Additional file 1 of A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Journal
Figshare
Topics
Liver physiology and pathology
article
Additional file 1 of A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
article en
Abstract
No abstract available for this paper.
Publication Tag
Figshare
Institutions
Queen's University Belfast (GB), Royal College of Surgeons in Ireland (IE), University of Liverpool (GB), Masaryk University (CZ), Sorbonne Université (FR), University of Oxford (GB), Agilent Technologies (Belgium) (BE), Antwerp University Hospital (BE), Hôpital Européen Georges-Pompidou (FR), Cancer Trials Ireland (IE), Institut Català d'Oncologia (ES), Hôpital Européen (FR), IFOM (IT), Candiolo Cancer Institute (IT), University of Turin (IT), Cardiff University (GB)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Additional file 1 of A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) · Figshare (2025) | TGRS Research Map | TGRS